Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above
Condition: Herpes Zoster Interventions: Biological: Low dose Recombinant Herpes Zoster Vaccine (CHO cells); Biological: High dose Recombinant Herpes Zoster Vaccine (CHO cells); Biological: Positive control; Biological: Placebo Sponsors: MAXVAX Biotechnology Limited Liability Company; Henan Center for Disease Control and Prevention Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 12, 2023 Category: Research Source Type: clinical trials
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Conditions: Osteosarcoma; Sarcoma; Sarcoma,Soft Tissue; Bone Tumor Intervention: Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130) Sponsors: Shanghai Yunying Medical Technology; Xi'an Honghui Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 9, 2023 Category: Research Source Type: clinical trials
